tris(dibenzylideneacetone)dipalladium

09/15/2008 - "Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo."
09/15/2008 - "Tris DBA showed potent antitumor activity in vivo against melanoma. "
09/15/2008 - "Tris DBA has activity against B16 murine and A375 human melanoma in vivo. "
09/15/2008 - "Tris DBA was tested on efficacy on proliferation of human and murine melanoma cells. "
07/09/2019 - "We tested the novel agent Tris DBA palladium and found that it was markedly more effective against GNAQ mutant melanomas than wild type uveal melanomas. "

01/01/2020 - "In the current study, we examined the therapeutic effects of Tris DBA on glomerular cell proliferation, renal inflammation, and immune cells. "
12/01/2020 - "The therapeutic effects of Tris DBA on glomerular cell proliferation and renal inflammation and mechanism of action were examined in a mouse model of IgAN. "
12/01/2020 - "Treatment of IgAN mice with Tris DBA resulted in markedly improved renal function, albuminuria and renal pathology, including glomerular cell proliferation, neutrophil infiltration, sclerosis and periglomerular inflammation in the renal interstitium, together with (Clin J Am Soc Nephrol. "
01/01/2020 - "Treatment of accelerated and severe lupus nephritis (ASLN) mice with Tris DBA resulted in improved renal function, albuminuria, and pathology, including measurements of glomerular cell proliferation, cellular crescents, neutrophils, fibrinoid necrosis, and tubulointerstitial inflammation in the kidneys as well as scoring for glomerulonephritis activity. "

12/01/2020 - "Treatment of IgAN mice with Tris DBA resulted in markedly improved renal function, albuminuria and renal pathology, including glomerular cell proliferation, neutrophil infiltration, sclerosis and periglomerular inflammation in the renal interstitium, together with (Clin J Am Soc Nephrol. "
01/01/2020 - "Treatment of accelerated and severe lupus nephritis (ASLN) mice with Tris DBA resulted in improved renal function, albuminuria, and pathology, including measurements of glomerular cell proliferation, cellular crescents, neutrophils, fibrinoid necrosis, and tubulointerstitial inflammation in the kidneys as well as scoring for glomerulonephritis activity. "

01/01/2016 - "Thus, further evaluation of tris DBA palladium for the treatment of pancreatic cancer is warranted."
01/01/2016 - "We found that tris DBA palladium decreased proliferation and colony formation of pancreatic cancer cells in vitro. "
01/01/2016 - "Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model."
01/01/2016 - "Based upon the signaling similarities between melanoma and pancreatic carcinoma, we evaluated the efficacy of tris DBA palladium in vitro and in vivo against pancreatic carcinoma. "
01/01/2016 - "We propose that NMT1 is a novel regulator of cilia formation and tris DBA palladium a novel inhibitor of cilia formation and metastasis in pancreatic cancer. "

10/01/2016 - "Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells."
10/01/2016 - "Here we tested impact of Tris (dibenzylideneacetone) dipalladium (Tris-DBA) on chronic lymphocytic leukemia (CLL) B-cell survival. "